These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Active vaccination after allogeneic bone marrow cell transplantation: a new option in the immunotherapy of cancer? Zöller M; Matzku S Arch Immunol Ther Exp (Warsz); 2002; 50(3):197-224. PubMed ID: 12098935 [TBL] [Abstract][Full Text] [Related]
5. Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy. Baxevanis CN; Perez SA; Papamichail M Cancer Immunol Immunother; 2009 Mar; 58(3):317-24. PubMed ID: 18704409 [TBL] [Abstract][Full Text] [Related]
6. Bio-immunotherapy for cancer in experimental studies and clinical application: current status and future challenges. Shen RN; Lu L; Kaiser HE; Broxmeyer HE In Vivo; 1994; 8(5):643-52. PubMed ID: 7727711 [TBL] [Abstract][Full Text] [Related]
7. Breast cancer immunotherapy. Zhou J; Zhong Y Cell Mol Immunol; 2004 Aug; 1(4):247-55. PubMed ID: 16225767 [TBL] [Abstract][Full Text] [Related]
9. Cancer immunotherapy: will expanding knowledge lead to success in pediatric oncology? Fry TJ; Lankester AC Hematol Oncol Clin North Am; 2010 Feb; 24(1):109-27. PubMed ID: 20113898 [TBL] [Abstract][Full Text] [Related]
10. Search for "weapons of mass destruction" for cancer -- immuno/ gene therapy comes of age. Wei MQ; Metharom P; Ellem KA; Barth S Cell Mol Immunol; 2005 Oct; 2(5):351-7. PubMed ID: 16368061 [TBL] [Abstract][Full Text] [Related]
11. Development of immunotherapy for the treatment of malignancies refractory to conventional therapies. Kim S; Haas GP; Hillman GG Cytokines Mol Ther; 1996 Mar; 2(1):13-9. PubMed ID: 9384685 [TBL] [Abstract][Full Text] [Related]
12. Cellular therapy to control tumor progression. Kapp M; Rasche L; Einsele H; Grigoleit GU Curr Opin Hematol; 2009 Nov; 16(6):437-43. PubMed ID: 19587587 [TBL] [Abstract][Full Text] [Related]
13. [The repetitive immune cell transfer therapy combining non-myelosuppressive chemotherapy for patients with advanced and refractory cancer]. Toh U; Fujii T; Tayama K; Yanaga H; Yokoyama G; Yamaguchi M; Horiuchi H; Sasatomi T; Takamori S; Shirouzu K; Seki N; Yamana H Gan To Kagaku Ryoho; 2004 Oct; 31(11):1649-51. PubMed ID: 15553672 [TBL] [Abstract][Full Text] [Related]
14. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice. Proietti E; Greco G; Garrone B; Baccarini S; Mauri C; Venditti M; Carlei D; Belardelli F J Clin Invest; 1998 Jan; 101(2):429-41. PubMed ID: 9435316 [TBL] [Abstract][Full Text] [Related]
17. Chemo-immunotherapy and chemo-adoptive immunotherapy of cancer. Gomez GG; Hutchison RB; Kruse CA Cancer Treat Rev; 2001 Dec; 27(6):375-402. PubMed ID: 11908930 [TBL] [Abstract][Full Text] [Related]
18. [Immunotherapy for cancer--modern immunologic strategies in oncology]. Halama N; Zoernig I; Jäger D Dtsch Med Wochenschr; 2008 Oct; 133(41):2105-8. PubMed ID: 18985564 [TBL] [Abstract][Full Text] [Related]
19. [Application of gene therapy in tumor adoptive immunotherapy]. Wang C; Zhao Y Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2008 Apr; 25(2):482-6. PubMed ID: 18610648 [TBL] [Abstract][Full Text] [Related]
20. Combining immune cell and viral therapy for the treatment of cancer. Thorne SH; Contag CH Cell Mol Life Sci; 2007 Jun; 64(12):1449-51. PubMed ID: 17404689 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]